On November 24, 2025 GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, reported a collaborative research agreement with Hokkaido University Hospital to support the development of its next-generation antibody-drug conjugate (ADC) GNX1021 in gastric cancer patients and lay the groundwork for future clinical trials in Japan. As part of the effort, the two parties will conduct a retrospective study evaluating the expression of branched Lewis B/Y (bLeB/Y) glycan antigen in gastric cancer patients and assess its association with established clinical biomarkers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
According to the National Cancer Center Japan (NCC), gastric cancer is the third most common cancer and the fourth leading cause of cancer-related deaths in Japan. In 2024, it is projected to account for 115,100 new cases and 39,900 deaths, highlighting the urgent need for new treatment options. Through this collaboration, GlycoNex and Hokkaido University Hospital will evaluate the prevalence and distribution of bLeB/Y expression in these Japanese gastric cancer patients and compare it to established clinical biomarkers, including HER2, CLDN18, PD-L1, and MMR. The goal is to better define the patient population most likely to benefit from GNX1021 treatment, ultimately enhancing the probability of clinical success.
"Our collaboration with Hokkaido University Hospital marks an important step in understanding how bLeB/Y expression can guide treatment strategies for gastric cancer patients," said Dr. Mei-Chun Yang, CEO of GlycoNex. "By building a stronger scientific foundation for GNX1021, we aim to advance the development of glycan-directed therapies that expand treatment options beyond today’s HER2- and CLDN18-based approaches, ultimately addressing significant unmet needs in oncology."
GNX1021 has demonstrated potent tumor-suppressive activity across multiple preclinical gastric cancer models, including settings resistant to existing HER2- and CLDN18-targeted therapies. Building on these findings, GlycoNex has advanced the program through pre-fill and toxicology testing and is preparing for regulatory submissions in Taiwan and Japan. Phase I clinical trials are planned to begin in 2026, with the goal of delivering a novel treatment option for gastric cancer patients who remain underserved by current targeted approaches.
(Press release, GlycoNex, NOV 24, 2025, View Source [SID1234660916])